Latest News

CAMBRIDGE, Mass. — Skylark Bio, a clinical-stage biotechnology company developing precision genetic medicines for monogenic disorders, is expanding its pipeline with SKY-AS, a differentiated gene therapy candidate designed to restore UBE3A expression in individuals with Angelman syndrome (AS). SKY-AS represents the company’s first central nervous system (CNS) development program and...
TAIPEI, Taiwan — SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced new preclinical data evaluating unmodified human γδ T cells in glioblastoma (GBM) — the Company’s unmodified γδ T cell therapy platform (the...
Experts have said they may develop a more effective kit for detecting sleeping sickness and medication against the condition in the next three years. Scientists at the Institute of Primate Research (IPR) in Nairobi and their counterparts from the European Union are currently working on what they say are more...
For more than 3000 years, hundreds of millions of people have died or been left permanently scarred or blind by the relentless, incurable disease called smallpox. In 1967, Dr. D.A. Henderson became director of a worldwide campaign to eliminate this disease from the face of the Earth. SMALLPOX—THE DEATH OF...
A study of patients who were smokers at the time of early-stage non-small cell lung cancer (NSCLC) diagnosis revealed possible links to improved survival outcomes with smoking cessation in this population. The study results were reported in the journal Annals of Internal Medicine. This prospective, observational study was conducted at the...
SEONGNAM, South Korea — SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in its global Phase 1b/2 clinical trial evaluating SNB-101 (API: SN-38), a nanoparticle anticancer agent, in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC). This multi-center...
EONGNAM, South Korea — In a strong endorsement of its cutting-edge drug delivery technology, SN BioScience announced that its anticancer candidate SNB-101 has been selected as a clinical-stage project under the 2025 Korea Drug Development Project, a government-initiated program led by the Korea Drug Development Fund (KDDF). The program includes two years...